Emory Expands Research on MDMA-Assisted Therapy for PTSD

Emory University is set to expand its research into the potential benefits of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), thanks to a significant federal grant recommended by the U.S. Department of Defense. The $4.9 million in funding will support a new clinical trial in collaboration with the University of Texas Health Science Center in San Antonio and the Strong Star Consortium, a national research network focused on PTSD treatment.

New Clinical Trial Focuses on Military Personnel

The upcoming study will involve 100 participants from active-duty military, National Guard, and reservist populations. It will evaluate the effects of a single supervised dose of MDMA, followed by two weeks of daily therapy sessions using prolonged exposure, an approach that helps individuals gradually confront trauma-related memories and situations in a controlled environment. The study has received approval from both the FDA and the DEA, with all participants being carefully screened for safety. The same regulatory processes will be followed for the newly funded trial.

Implications for PTSD Treatment

If successful, this research could contribute to a growing body of evidence supporting MDMA-assisted therapy as a tool for patients experiencing PTSD, particularly for military populations. However, until further studies confirm its safety and efficacy, MDMA remains a Schedule I controlled substance, only available in clinical research settings.

As Georgia continues to monitor developments in psychedelic-assisted therapy, Emory’s research represents an important step in understanding how MDMA may be integrated into future mental health treatments. GAPT will continue to follow and report on these important advancements, providing the public and healthcare professionals with updates on the latest clinical research and policy changes related to psychedelic-assisted therapy in Georgia.